Depemokimab: 7 agencies, 2026–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused depemokimab: all 5 decisive outcomes across 4 agencies were positive or positive with restrictions.
Every record falls within a 0.6-year window, 22 Jan 2026 to 25 Aug 2026 — a compressed review cycle.
No assessment is on file from HAS (France), SMC (Scotland), PHARMAC (New Zealand) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for depemokimab, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
3 distinct indication wordings are recorded for depemokimab by the agencies that label one in English (AWMSG, NICE and PBAC).
1 of these 8 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
The systems moved almost together: all 6 agencies opened a file on depemokimab within a year of one another, starting with NICE (England) on 22 Jan 2026.
Activity is concentrated rather than steady: 6 of 6 dated records fall in 2026 alone.
DMC (Denmark) is the only agency to have returned to depemokimab, recording 2 separate entries.
7 of the 18 agencies in this archive hold a record for depemokimab.
The full ledger for depemokimab reads 4 recommended, 1 restricted, 1 pending and 1 terminated, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2026 | Uncontrolled severe eosinophilic asthma | Recommended | source |
| DMC (Denmark) | 24 Jun 2026 | Vedligeholdelsesbehandling af svær eosinofil astma hos patienter fra 12 år og ældre, som ikke er tilstrækkeligt kontroll… | Direkte indplacering | source |
| CIPM (Spain) | 20 May 2026 | LABORATORIO MEDICAMENTO FORMATO CN Precio € Criterios para la financiación GLAXOSMITHKLINE SA EXDENSUR 100 MG SOLUCION I… | financed by the SNS | source |
| CHUIKYO (Japan) | 8 Apr 2026 | エキシデンサー: cost-effectiveness evaluation (new product, high price or high sales) | evaluation under way | source |
| NICE (England) | 22 Jan 2026 | NICE TA1123 | terminated appraisal | source |
3 further decisions for depemokimab, across 3 agencies, are not shown here. They include the most recent record on file, 25 Aug 2026 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 3 further source documents.
Related molecules
- mepolizumab — same ATC class R03D — Obstructive airway diseases
- omalizumab — same ATC class R03D — Obstructive airway diseases
- benralizumab — same ATC class R03D — Obstructive airway diseases
- tezepelumab — same ATC class R03D — Obstructive airway diseases
- montelukast — same ATC class R03D — Obstructive airway diseases
- roflumilast — same ATC class R03D — Obstructive airway diseases
Coverage: 8 decisions for depemokimab from 7 agencies, 2026 to 2026. Data to 7 Sep 2026. ATC class R03D — Obstructive airway diseases. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.